J.P. Morgan Comments On Eli Lilly Investor Day

According to J.P. Morgan, Eli Lilly & Company LLY investor day focused on the assumptions supporting the company's $20bn/$3bn trough sales and net income assumptions as well as Lilly's late stage pipeline aimed at accelerating growth off these trough levels. J.P. Morgan said that it remains comfortable with the company's trough 2014 sales/net income targets and, while be believe that Lilly has put together a broad late-stage portfolio, data for many of these assets remains 18-24 months away. “We have updated our model to incorporate some of the incremental guidance updates Lilly provided at yesterday's meeting in addition to other modest adjustments.” Eli Lilly & Company closed yesterday at $37.53.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsEli Lilly & Co.Health CareJ.P. MorganPharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!